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Searching to identify adverse effects data: an overview of current evidence and guidance 
Abstract 
Objective: Methodological research has been undertaken to investigate the many challenges in 
searching for adverse effects data. It is imperative that the search approach adopted in systematic 
reviews is based on the best available evidence. We provide a detailed summary of the results and 
implications of the current evidence base to assist future searches for adverse effects. 
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Study Design and Setting: This paper is a narrative review from the authors of the Cochrane 
Handbook chapter on adverse effects. 
Results: The specified search strategy must be based on the PICO (Population, Intervention, 
Comparator, Outcome(s)) format for question formulation and appropriate study designs for 
adverse effects data. Search filters and suggested search terms are available for the adverse effects 
of drug, medical devices and surgical interventions. The use of generic adverse effects terms (such as 
harms, and complications) as textwords and indexing terms and specific adverse effects terms (such 
as rash and wound infection) are warranted. Searching databases beyond MEDLINE has proven 
useful, as well as the use of non-database sources. 
Conclusion: This paper provides the most up to date evidence-based guidance in identifying adverse 
effects data in the literature. It will support searchers and researchers evaluating the potential for 
harm of medical interventions in systematic reviews. 
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Adverse effects; literature searching; systematic reviews; complications; information retrieval 
 
What is new? 
Key finding 
• Guidance on searching for adverse effects is underpinned by methodological research and 
evidence based. 
 
What this study adds to what was known? 
• Adverse effects search strategies should aim to maximise sensitivity over precision in order 
to retrieve the totality of the evidence for appraisal. 
• Published adverse effects search filters have demonstrated approaching 90% sensitivity but 
are unlikely to achieve a fully comprehensive list of records. 
What is the implication and what should change now? 
• Adverse events searching should be tailored to suit the intervention of interest. While search 
filters are available for drug, medical devices and surgical interventions search filters for the 
adverse effects of other types of interventions are now warranted. 
• Searches should aim to capture adverse effects data from a broad selection of sources and 
not rely on a single source, such as MEDLINE. 
• To reduce the potential for publication bias reviewers should attempt to search for 
unpublished data for relevant adverse effects information in addition to published sources. 
 
Introduction 
The objective of this paper is to assist research teams to deal with the challenges of undertaking a 
robust search for adverse effects data for a systematic review of medical interventions. The need for 
this paper arises from the major challenges in searching for adverse effects in systematic reviews. 
First, adverse effects are not always pre-specified and new or previously unknown adverse effects 
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are difficult to predict and specify in searches. Second, there can be a huge (almost limitless) range 
of adverse effects to consider. Third, reporting of adverse effects in studies may be inconsistent 
and/or less detailed when adverse effects are not the primary focus, or considered to be outcomes 
that are of lesser importance. This leads to poor database indexing and few relevant adverse effects 
terms appearing in the database record. Fourth, the terminology surrounding adverse effects is 
inconsistent, meaning that searchers need to use multiple synonyms in their search strategies. Fifth, 
different search approaches are required to identify adverse effects of different types of 
interventions (Farrah 2013, Golder 2014, Farrah 2016, Golder 2017). 
In addition it is not always appropriate to limit the searches to randomised controlled trials (RCTs). A 
small short-term study (such as an RCT) may adequately capture common, immediately apparent 
adverse effects (such as skin reaction after injection), whilst other study types (for instance, case-
control) will be needed for very rare, long-term adverse effects (Loke 2011). Searching for these non-
RCT study types can be problematic due to inconsistent use of terminology and poor indexing which 
has led to search filters with poor sensitivity . 
Lastly, there is no single comprehensive source for adverse effects data and unpublished data may 
be of particular importance (Golder 2010, Loke 2011, Alves 2012, Golder 2012d, Golder 2014).  
With all these issues in mind, evidence based guidance to help searchers is urgently warranted.  
Question Formulation 
As with other systematic reviews, the first step to informing a search strategy is to establish a PICO 
(Population, Intervention, Comparator, Outcome(s)) format for the adverse effects review question.  
 
Population [P]: If study is population specific then relevant terms will need to be included to identify 
population of interest but if evaluating adverse effects across all conditions then population specific 
terms can be omitted. When searching with specific population terms the review team need to be 
careful to try not to miss papers due to a lack of description of the population in the title, abstract or 
indexing fields. For example, a paper on ‘Fracture risk with rosiglitazone and pioglitazone compared’ 
did not mention diabetes in the bibliographic record. 
Intervention [I]: It is almost always necessary to include intervention terms in the search. When 
defining the intervention, reviewers will need to consider the clinical heterogeneity across related 
studies in their mode of action and their potential to cause harm (Loke 2011, CIOMS 2016, Zorzela 
2016). For example, systematic reviews of pharmacological interventions should not assume that all 
drugs in a class will have the same potential to cause adverse effects (Centre for Reviews and 
Dissemination 2009). 
Comparator [C]:  Including search terms for comparators is rarely done, partly because there is a 
very diverse range of potential comparators. Incorporating studies with a placebo group or a no 
active treatment group in the systematic review is more straightforward because observed adverse 
effects can then be more reliably attributed to the intervention. While a placebo-controlled 
approach has greater internal validity there is a loss of generalisability to healthcare areas if the 
relative harms of two or more existing interventions are being considered.   
Outcome [O]:  Review questions may incorporate all potential adverse effects (exploratory 
approach) or be focused on a set of pre-specified adverse effect (confirmatory approach) or a hybrid 
between the two. In the past, database records contained few specific terms relating to adverse 
effects in the title, abstract or database indexing. However, significant improvements have occurred 
in adverse effects reporting in database records so recent literature is more likely to be retrieved 
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using adverse effects search terms, and there is less need for scanning the full text of papers (Golder 
2011, Golder 2012b, Golder 2018a). 
Named adverse effects can be identified from: clinicians’ observations in published reports, patients’ 
reports (such as internet forums), scoping reviews, regulatory agencies (such as Food and Drug 
Administration) or tertiary sources (such as British National Formulary, Meyler's Side Effects of 
Drugs). Reviewers could opt to limit the adverse effects of interest based on severity, timing, or 
plausibility of the intervention’s effect. 
Study Design [S]: When carrying out reviews of adverse effects authors may opt for a wide range of 
included study designs because rare adverse events observed over the longer term may not be 
detected as part of a traditional prospectively designed RCT (Loke 2007, Chou 2010, Golder 2011, 
Loke 2011). Inclusion criteria in controlled trials may exclude participants of increased risk of harm, 
which may not be representative of everyday practice (such as children, women of childbearing age, 
people with co-morbidities or frail older adults), and the duration of follow-up may not capture long-
term adverse effects (Loke 2007). Observational cohorts, case-control studies, case series, post-
marketing surveillance, or case reports may potentially provide more relevant information for 
certain types of adverse effects (Loke 2007, Chou 2010, Golder 2011, Loke 2011, Relevo 2011). If the 
review is using a confirmatory approach it is more appropriate to prioritize stronger RCT evidence 
(Chou 2010).  Search terms based on study design are reasonable for identifying RCTs. However, the 
diverse range of study designs used in assessing adverse effects (cohort, case-control, cross-
sectional) creates major challenges in developing a reliable search string to pick out these specific 
types of studies. 
 
Designing adverse effects search strategies 
It is unlikely that a search for efficacy or effectiveness studies will be broad enough to incorporate 
adverse effects in a comprehensive manner unless the original search was restricted to a search for 
the intervention alone (Loke 2007, Golder 2009, Golder 2012b, Golder 2014). Thus, generally a 
search for adverse effects will need to be carried out alongside the search for effectiveness. As with 
all searches, the involvement of an information specialist (Golder 2014, Zorzela 2014, CIOMS 2016) 
and peer review of search strategies is advised (McGowan 2016).  The PRESS guidelines are helpful in 
carrying out the peer review process (McGowan 2016).  
Searches need to be as sensitive as possible to reduce the potential risk of bias and a false negative 
error (Type II error), whereby an intervention is judged incorrectly as having no significant evidence 
of harm (Loke 2011). Multiple database and platform-specific search strategies should be piloted 
during the design stage (Golder 2006, Golder 2009, Relevo 2011, Golder 2012a, Golder 2012b, 
Golder 2014). An iterative approach to generating search strategies will enable structured 
comparisons of retrieved results in order to evaluate optimum approaches (Golder 2009).  
A highly sensitive search strategy is likely to be associated with poor precision. A search with high 
sensitivity search will typically generate several thousand abstracts to screen for eligibility, with 
potentially high numbers of results needing to be read in full in order to identify a single eligible 
record (Golder 2009, Golder 2012b). The scale of resources required can often be determined using 
careful scoping exercises when drafting the review question. 
 
Adverse effects search terms 
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Both specific and generic search techniques have strengths and limitations. Recommended practice 
is to consider the use of the two search methods in combination: generic adverse effects terms (such 
as ‘side effects’, ‘harms’ and ‘adverse reactions’) using the ‘OR’ function along with specific adverse 
effects terms (such as ‘headache’, ‘blood loss’, or ‘dysphagia’) (Golder 2014). It is also advisable to 
combine index terms and free-text searching to increase search sensitivity and reduce the chance of 
missing relevant material. However, this method may still lack the high sensitivity required for 
systematic reviews due to poor reporting and indexing of adverse effects in bibliographic records In 
addition, some compromise in this approach may be required in situation where unmanageable 
numbers of records for screening are retrieved. 
Search fields that can be searched using generic adverse effects terms are: index terms (such as 
MeSH or Emtree), subheadings (linked to indexing terms or not), and text words (such as in the title 
or abstract). 
Index terms 
The index terms relevant to search strategy development for adverse effects in MEDLINE and 
Embase are listed in Table 1. Many of these terms can be exploded (whereby narrower index terms 
are included) to achieve increased sensitivity. The most relevant indexing terms for adverse effects 
are dependent on the type of intervention evaluated. In MEDLINE the top performing search term in 
relation to sensitivity for drug interventions is the use of  ‘adverse effects (ae)’ as a floating 
subheading (Golder 2006), for surgery it is the search term ‘complication*’ (where * represents a 
wildcard) in the title and abstract (Golder 2018a, Golder 2018b) and for medical devices it is 
‘complicat*’ in the title and abstract (Golder 2018c). In Embase, the search term that achieves 
highest sensitivity for drug interventions is the floating subheading ‘adverse drug reaction (ae)’, for 
surgery it is ‘complication*’ in the title and abstract (Golder 2018a, Golder 2018b) and for medical 
devices it is the floating subheading ‘complication (co)’ (Golder 2018c). Note that the generalisability 
of these sensitivity results is unknown although they provide useful indications to review teams.  
Table 1: Index terms for adverse effects in MEDLINE and Embase 
MEDLINE MeSH Index Terms 
 
Embase Emtree Index Terms 
Drug Intervention 
Drug Intervention abnormalities, drug induced/  
 
adverse drug reaction/ 
adverse drug reaction reporting systems/ 
 
drug hypersensitivity/ 
 
drug hypersensitivity/ 
 
drug monitoring/ 
 
drug monitoring/ 
 
drug recall/ 
 drug recalls/  
 
drug safety/ 
 
drug related side effects and adverse reactions/ drug surveillance program/ 
 
long term adverse effects/ 
 
drug toxicity/ 
 
poisoning/ 
 
intoxication/ 
 
safety-based drug withdrawals/ 
 
side effect/ 
 
substance-related disorders/ 
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Subheadings 
The most useful search method for retrieving adverse effects results is to employ subheadings 
(sometimes referred to as qualifiers) (Golder 2006, Golder 2014, Golder 2018a). Although rarely 
recommended in reviews of treatment benefit, in reviews incorporating adverse effects they are 
particularly useful in augmenting sensitivity and precision of searches (Golder 2012a, Golder 2012c, 
Golder 2014, Golder 2014, Golder 2014). Relevant adverse effects subheadings in MEDLINE and 
Embase are listed in table 2.  
Table 2: Subheadings in MEDLINE and Embase 
Drug Intervention/Medical Device 
 product surveillance postmarketing/  postmarketing surveillance/ 
  product recall/ 
Surgical Procedure 
 intraoperative complications/  
 
 perioperative complication/ 
 
postoperative complications/ 
 
 postoperative complication/ 
 
postoperative pain/ 
 
 surgical risk/ 
Medical Device 
Medical device equipment contamination/ 
 
adverse device effect/ 
 equipment failure/ 
 
device recall/ 
 equipment failure analysis/ 
 
device safety/ 
 
equipment safety/ 
 
equipment safety/ 
 
medical device recalls/  
 
medical device complication/ 
safety-based medical device withdrawals/  
 
 
Non-drug Interventions 
  
 
complication/ 
 Hazards 
 risk assessment/ 
 
 
OVID MEDLINE  
 
OVID Embase 
/adverse effects (ae) /adverse device effect (am) 
/chemically induced (ci) /adverse drug reaction (ae) 
/complications (co) 
 
/complication (co) 
 /contraindications (ct) 
 
/drug toxicity (to) 
 /poisoning (po) 
 
/side effect (si) 
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Indexed subheadings can be searched attached to an indexing term or used independently. An 
example search string in MEDLINE is ‘Aspirin/adverse effects’ where ‘Aspirin’ is the MeSH term and 
‘adverse effects’ is the subheading. In Embase, an example search string is: ‘Acetylsalicylic-
acid/adverse-drug-reaction’ where ‘Acetylsalicylic-acid’ is the Emtree term and ‘adverse-drug-
reaction’ is the subheading.  
Subheadings can also be ‘free floating’ i.e. used without a thesaurus indexing term (Golder 2012a, 
Golder 2012c, Golder 2014,).  OVID MEDLINE examples are ‘ae.fs’ (adverse effects), ‘co.fs’ 
(complications), ‘po.fs’ (poisoning), ‘de.fs’ (drug effects) - where ‘.fs’ denotes a floating search. If 
required, in OVID MEDLINE the subheading ‘adverse effects’ can be exploded to include other 
subheadings (poisoning and toxicity) (Golder 2012a, Golder 2012b, Golder 2012c, Golder 2014). 
In OVID MEDLINE the search string ‘Aspirin/ae’ will retrieve results that have been indexed with the 
combination ‘Aspirin’ as a subject heading with ‘adverse effects’ attached as a subheading. Inputting 
the two search terms independently and combining with the AND search operator, for example, 
‘Aspirin/ AND ae.fs.’ will increase the sensitivity of the search strategy. 
Free-text terms 
Free-text terms searches (such as in the title or abstract) alone are unreliable at retrieving 
comprehensive results and should be used alongside thesaurus terms and/or subheadings (Golder 
2009).  Relevant free-text terms include (but is not limited to): ‘safe’, ‘safety’, ‘side effect*’, 
‘undesirable effect*’, ‘treatment emergent’, ‘tolerability’, ‘toxicity’, ‘adverse drug reaction*’, ‘adrs’, 
‘adverse effect*’, ‘adverse drug effect*’, ‘adverse reaction*’, ‘adverse event*’, ‘adverse outcome*’, 
‘complication*’, ‘harm’, ‘harmful’, ‘harms’, ‘risk’ (where * represents a wildcard). However, care 
needs to exercised with some of these terms because of the potential for a substantial amount of  
noise and irrelevant records, for example, articles  containing phrases such as ‘risk of bias’, ‘relative 
risk’, ‘patient safety’ and ‘self-harm’. Case studies have analysed the sensitivity of free-text terms 
and again indicate that the most useful terms are dependent on the type of intervention (Golder 
2006, Golder 2012b, Golder 2014, Golder 2018a, Golder 2018b, Golder 2018c).  
Search Filters 
A search filter is a predefined combination of search terms designed to retrieve information on a 
particular topic (Golder 2009, Golder 2012a, Golder 2012c).  
Although high sensitivity can be achieved with published drug adverse effects search filters, the full 
complement of relevant records are unlikely to be retrieved (Golder 2012a, Golder 2012c). For 
reviews of drug interventions the published search filter that displays the best sensitivity is by Golder 
et al 2006.  Research has also been undertaken to develop search filters for medical device adverse 
effects and surgical complications in MEDLINE and Embase (Golder 2018a, Golder 2018b). These 
filters have demonstrated the different terminology and indexing used for the adverse effects of 
different types of interventions (Box 1). For example, the term ‘complications’ is more frequently 
used with surgical procedures and terms related to ‘failure’ and ‘recall’ with medical devices (Box 1) 
(Golder 2018a, Golder 2018b). The sensitivity achieved with search filters varies. Whilst drug adverse 
effects search filters tend to achieve the highest sensitivity, adverse medical device effects filters 
achieve the lowest sensitivity. However, generally a sensitivity approaching at least 90% is achieved. 
Box 1: Search filters for medical devices, surgical procedures and drug interventions 
/toxicity (to) 
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Ovid MEDLINE Ovid Embase 
Medical Devices (Golder 2018c) 
complicat*.ti,ab. OR ae.fs. [adverse effects] 
OR safe*.ti,ab. OR exp postoperative 
complications/ OR failure*.ti,ab. OR 
adverse.ti,ab. OR co.fs. [complications] OR 
failed.ti,ab. OR exp equipment failure/ OR 
removal.ti,ab. OR equipment safety/ OR 
problem*.ti,ab. OR side effect*.ti,ab. OR 
harmful.ti,ab. OR tolerated.ti,ab. OR 
loosen*.ti,ab. OR Intraoperative 
complications/ OR migration.ti,ab. OR 
breakag*.ti,ab. OR discomfort.ti,ab. OR 
displacement.ti,ab. OR detrimental adj2 
effect*.ti,ab. OR untoward effects.ti,ab. 
co.fs. [Complication] OR complicat*.ti,ab. 
OR safe*.ti,ab. OR failure*.ti,ab. OR exp 
medical device complication/ OR 
adverse.ti,ab. OR failed.ti,ab. OR exp 
postoperative complication/ OR 
problem*.ti,ab. OR side effect*.ti,ab. OR 
discomfort.ti,ab. OR loosen*.ti,ab. OR 
removal*.ti,ab. OR complications.kw. OR 
migration.ti,ab. OR ae.fs. [adverse drug 
reaction] OR device related events.ti,ab. OR 
adverse effects/ OR device safety/ OR 
safety/ OR peroperative complication/ OR 
tolerated.ti,ab. OR failing.ti,ab. 
Surgical Procedures (Golder 2018a, Golder 2018b) 
complication*.ti,ab. OR ae.fs. [adverse effects] 
OR safe*.ti,ab. OR co.fs. [complications] OR 
postoperative complications/ 
complication*.ti,ab. OR co.fs. [Complication] 
OR safe*.ti,ab. OR ae.fs. [adverse drug reaction] 
OR postoperative morbidity.ti,ab. OR surgical 
risk/ OR complication/ OR postoperative 
complication/ OR procedure related.ti,ab. 
Drug interventions (Golder 2006) 
ae.fs. [adverse effects] OR co.fs. [complications] 
OR de.fs. [drug effects] OR safe.ti,ab. OR 
safety.ti,ab.  OR side-effect*.ti,ab.  OR 
undesirable effect*.ti,ab.  OR treatment 
emergent.ti,ab.  OR tolerability.ti,ab.  OR 
toxicity.ti,ab. OR adrs OR (adverse adj2 (effect 
OR effects OR reaction OR reactions OR event 
OR events OR outcome OR outcomes)).ti,ab. 
(“DRUG”/ae, to) [adverse drug reaction, drug 
toxicity] OR safe.ti,ab. OR safety.ti,ab. OR side-
effect*.ti,ab. OR undesirable effect*.ti,ab. OR 
treatment emergent.ti,ab. OR tolerability.ti,ab. 
OR toxicity.ti,ab. OR adrs.ti,ab. OR (adverse 
adj2 (effect OR effects OR reaction OR reactions 
OR event OR events OR outcome OR 
outcomes)).ti,ab. 
N.B. All search filters provided higher sensitivity when ORed with specific named adverse effect 
terms. “DRUG” refers to where searches need to insert the specific drug(s), * represents a wildcard,  
/ indicates indexing term,  .ti,ab. is title and abstract, .fs. is floating subheading and adj is adjacency. 
If search filters are used it is very important to ensure they are specifically designed and validated 
according to the data sources being used (such as MEDLINE via OVID), and that they are up to date. 
Published search filter resources for adverse effects are provided by the InterTASC Information 
Specialists' Sub-Group (ISSG) website at https://sites.google.com/a/york.ac.uk/issg-search-filters-
resource/adverse-events-filters.  
Adverse effects data sources    
It is essential to not restrict adverse effect review searches to a single source, or a limited 
combination of databases (Golder 2012d).  Performing a search in MEDLINE alone is not 
recommended and a broad selection of database and non-database sources are required (Golder 
2010, Golder 2012d, Golder 2013).  
A case study reviewing adverse effects of thiazolidinedione use in patients with type 2 diabetes 
mellitus tested over 60 sources and demonstrated that a wide range of sources were required 
(Golder 2012d). Searching MEDLINE alone would have failed to retrieve 66% of relevant references 
while using MEDLINE, Embase and CENTRAL would have failed to retrieve 57% of relevant references 
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(Golder 2012d). To identify all the included studies for this review multiple databases needed to be 
searched along with reference checking and industry sources. 
In another case study of a review of a medical device the sources required to identify the evidence 
included: Science Citation Index (SCI), Embase, CENTRAL, and either MEDLINE or PubMed, in 
addition to author contact, reference checking and use of current awareness services (for example, 
establishing alerts in Zetoc) (Golder 2014).  The choice of viable sources should always be guided by 
the subject area and the review question (Golder 2012d).  
 
Table 3: A non-exhaustive list of sources that include adverse effects data (adapted from 
Relevo  2011)  
Source category Source examples 
Primary databases 
MEDLINE, Embase, Central Register of Controlled Trials (CENTRAL), Science 
Citation Index (SCI), Social Science Citation Index (SSCI)
 
Specialised 
databases  
TOXLINE, Drug Adverse Reaction Target (DART), PsycINFO, Physiotherapy 
Evidence Database (PEDro), Cumulative Index to Nursing and Allied Health 
Literature (CINAHL Complete)
 
Grey Literature 
Clinical trial registries: 
ClinicalTrials.gov  
International Clinical Trials Registry Platform (ICTRP) 
Industry Trial Registries and Regulatory authorities:  
Manufacturer trial registries 
Medicines and Healthcare products Regulatory Agency www.mhra.gov.uk/ 
Food and Drug Administration  
www.fda.gov/medwatch;  
European Medicines Agency:  
http://www.ema.europa.eu/ema/ 
Online portals: 
Open Grey http://www.opengrey.eu/ 
Conference proceedings: 
Conference Proceedings Citation Index (CPCI); 
Conference Papers Index (CPI) 
Individual Conference websites 
Theses: 
Proquest Dissertation and Theses 
British Library EThOS 
Industry Clinical 
Study Report 
Requests 
Clinical Study Reports (CSR) requests can be made via the Wellcome Trust 
sponsored data sharing resource:   
https://www.clinicalstudydatarequest.com/ 
Current sponsors include:  Astellas, Bayer, Boehringer, Ingelheim, Daiichi 
Sankyo, Eisai, GlaxoSmithKline, Lilly, Novartis, Roche, Sanofi, Takeda, UCB, 
and ViiV Healthcare. 
Yale Open Access Data that has  results  available for >200 trials  
http://yoda.yale.edu/ 
Requests from companies external to the data sharing agreement can be 
made by direct contact. For example:    
MERCK - www.merck.com/mrl/clinical_trials/ 
AstraZeneca - www.astrazenecaclinicaltrials.com/ 
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Unpublished data sources 
For the purposes of this guidance unpublished sources are defined as sources that do not appear in a 
peer-reviewed journal (Golder 2010, Golder 2016) including: Clinical Study Reports, trial registries, 
conference proceedings, PhD theses, and spontaneous reporting resources (Table 3). To reduce 
selective reporting bias that may prioritise evidence of benefit it is strongly encouraged that 
reviewers search unpublished sources in parallel to published sources and contact study authors to 
request further information if published data could be incomplete. (Chou 2010, Loke 2011, Wieseler 
2013). However, approximately less than half of systematic reviews incorporating adverse effects 
data currently search for  unpublished data (Golder 2016). Failing to do this can lead to false-
negative errors in estimates of harm (Golder 2010, Wieseler 2013, Golder 2016, Golder 2016, Gorrell 
2016, Rosati 2016, Schroll 2016).  
Mandatory changes applied to trials regulated by the Food and Drug Administration (FDA) regarding 
the submission of adverse events data to Clinicaltrials.gov (Zarin 2016) and the legislated publication 
of clinical data by the European Medicines Agency (EMA) means that previous accessibility 
limitations are improving (EMA). Requests to access CSRs directly from certain industry sponsors can 
be made via a publicly accessible website: Clinical study data request (CSDR) (Strom 2016).  
When unpublished data are identified, researchers can never be clear whether all relevant studies 
have been located or how representative it is (Song 2010, Song 2012). Accessing unpublished data 
can be problematic in terms of delays in access and once received the data itself may be in non-
standard formats so that a robust meta-analysis is difficult to undertake, and it may place heavy 
demands upon the project’s resources (Wieseler 2013, Golder 2016, Golder 2016, Schroll 2016, 
Strom 2016). Consequently, data access issues should be considered at the planning stage. 
Including unpublished data sources can provide more detailed information on adverse events than 
publicly available sources. It has been demonstrated that fewer adverse effects are reported in 
published data (43%) compared to unpublished data (83%), and a wider range of named adverse 
Pfizer -  www.pfizer.com/research/clinical_trials 
Forward citation   
search 
Example interfaces include: Scopus, Web of Science, Google Scholar
 
Backward citation 
search 
Target specific references identified in key research articles 
Corresponding with 
researchers/authors 
Contact corresponding authors of key articles identified in search results for 
further information 
Hand search Target specific journals out of scope of previously searched databases  
Spontaneous 
reporting  
Adverse Drug Reactions 
http://ww1.adverse-drug-reaction.net/ 
UK Yellow card scheme 
https://yellowcard.mhra.gov.uk/the-yellow-card-scheme/  
Food and Drug Administration- Adverse Event Reporting System 
https://open.fda.gov/data/faers/ 
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effects are listed in unpublished data (Golder 2016). When published and unpublished data originate 
from the same study the unpublished version is more likely to contain adverse effects data (95%) 
compared to the published version (46%) (Golder 2016). Similarly, in other research, inconsistencies 
were evident with adverse effects in published documents coded to appear less severe with reduced 
incidence when compared to the unpublished CSRs. Adverse events reported in the published paper 
were in a range of 3% to 33% of those reported in the corresponding CSR summaries (Schroll 2016). 
When discrepancies between published and unpublished data are discovered it is recommended to 
attempt a sensitivity analysis to determine the potential impact upon review findings, and to contact 
study authors to clarify potential causes of disparity.    
These additional search requirements are likely to increase demands on time and resources for the 
review team; however, including unpublished material may modify critical conclusions regarding the 
safety of medicinal products and increase precision of estimates incorporated in meta-analyses 
(Golder 2008, Golder 2016). It is recommended that review authors specify the number of 
unpublished studies identified and document where details of adverse effects data were inaccessible 
(Golder 2016).  
Reporting search strategies 
If adverse effects data are reviewed in combination with data on treatment benefit, the search 
history identifying adverse effects data requires a separate report, presented in full.  When reporting 
the search history for adverse effects reviewers should adhere to the Methodological Expectations 
for Cochrane Intervention Reviews (MECIR) guidelines or the PRISMA harms extension (Zorzela 2016, 
Higgins 2018). It is important to report the search strategy as it was run with exact search terms and 
relevant truncation, the dates of searches completed, and any limits imposed so it could be 
reproduced in the future and readers can assess the methods used (Golder 2009). It is particularly 
important to report all the sources used - both published and unpublished – to enable its 
comprehensiveness to be judged. 
 
Conclusion 
Searching for adverse effects data for systematic reviews is challenging but feasible and essential. 
How searching is carried out and which sources are used, will determine what adverse effects are 
found.  The search phase is of critical importance and it is strongly advised to involve an information 
specialist (Golder 2014, Zorzela 2014, CIOMS 2016).  Research must continue to inform practice and 
lead to further improvement in the quality of searches. Other types of interventions are not covered 
by the available search filters, for example, physical or psychological interventions, diagnosis or 
screening. Search filters for adverse effects of interventions beyond drugs, medical devices and 
surgical interventions are therefore required.  
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What is new? 
Key finding 
• Guidance on searching for adverse effects is underpinned by methodological research 
and evidence based. 
 
What this study adds to what was known? 
• Adverse effects search strategies should aim to maximise sensitivity over precision in 
order to retrieve the totality of the evidence for appraisal. 
• Published adverse effects search filters have demonstrated approaching 90% 
sensitivity but are unlikely to achieve a fully comprehensive list of records. 
What is the implication and what should change now? 
• Adverse events searching should be tailored to suit the intervention of interest. 
While search filters are available for drug, medical devices and surgical interventions 
search filters for the adverse effects of other interventions are now warranted. 
• Searches should aim to capture adverse effects data from a broad selection of 
sources and not rely on a single source, such as MEDLINE. 
• To reduce the potential for publication bias reviewers should attempt to search for 
unpublished data for relevant adverse effects information in addition to published 
sources. 
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